ERBB2 and breast carcinoma: A meta-analysis [12] found the prevalence of germline TP53 mutations to be 7.7% in women with breast cancer < 30 years old without a LFS family history, and a 7% prevalence of TP53 mutations amongst women < 31 years old with a HER2-positive breast cancer.